Literature DB >> 15825131

Association of celiac disease and intestinal lymphomas and other cancers.

Carlo Catassi1, Italo Bearzi, Geoffrey K T Holmes.   

Abstract

Celiac disease (CD) is associated with intestinal lymphoma and other forms of cancer, especially adenocarcinoma of the small intestine, of the pharynx, and of the esophagus. Enteropathy-associated T-cell lymphoma (EATL) is a rare form of high-grade, T-cell non-Hodgkin lymphoma (NHL) of the upper small intestine that is specifically associated with CD. This NHL subtype arises in patients with either previously or concomitantly diagnosed CD. In a subgroup of patients, there is progressive deterioration of a refractory form of CD. EATL derives from a clonal proliferation of intraepithelial lymphocytes and is often disseminated at diagnosis. Extraintestinal presentations are not uncommon in the liver/spleen, thyroid, skin, nasal sinus, and brain. The outlook of EATL is poor. Recent studies indicated that (1) CD is associated with a significantly increased risk for NHL, especially of the T-cell type and primarily localized in the gut (EATL); (2) the CD-lymphoma association is less common than previously thought, with a relative risk close to 3; (3) CD screening is not required in patients with NHL of any primary site at the onset, unless suggested by specific findings (T-cell origin and/or primary gut localization). The risk of NHL associated with clinically milder (or silent) forms could be lower than in typical cases of CD. Several follow-up studies suggest that the GFD protects from cancer development, especially if started during the first years of life. Strict adherence to the GFD seems to be the only possibility of preventing a subset of rare but very aggressive forms of cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15825131     DOI: 10.1053/j.gastro.2005.02.027

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  77 in total

1.  Dermatitis Herpetiformis: Rare Cutaneous Manifestation of Colon Adenocarcinoma.

Authors:  Justin Hartke; Julian Trevino; Salma Akram
Journal:  J Gastrointest Cancer       Date:  2012-09

2.  Review.

Authors:  Mohammad Azam; Maire Buckley; Richard J Farrell
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-04

Review 3.  Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models.

Authors:  Aya M Westbrook; Akos Szakmary; Robert H Schiestl
Journal:  Mutat Res       Date:  2010-03-16       Impact factor: 2.433

4.  Occurrence of overt celiac disease in the elderly following total thyroidectomy.

Authors:  M Caputo; R Brizzolara; M Schiavo; C Salmaso; G Pesce; M Bagnasco
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

Review 5.  Hematologic manifestations of celiac disease.

Authors:  Thorvardur R Halfdanarson; Mark R Litzow; Joseph A Murray
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

Review 6.  Celiac disease: is the atypical really typical? Summary of the recent National Institutes of Health Consensus Conference and latest advances.

Authors:  Swati Gadewar; Alessio Fasano
Journal:  Curr Gastroenterol Rep       Date:  2005-12

Review 7.  An approach to duodenal biopsies.

Authors:  S Serra; P A Jani
Journal:  J Clin Pathol       Date:  2006-05-05       Impact factor: 3.411

Review 8.  Celiac disease: pathogenesis of a model immunogenetic disease.

Authors:  Martin F Kagnoff
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

Review 9.  The role of ultrasonography in patients with celiac disease.

Authors:  Mirella Fraquelli; Valentina Sciola; Chiara Villa; Dario Conte
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

10.  Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience.

Authors:  A Al-Toma; W H M Verbeek; M Hadithi; B M E von Blomberg; C J J Mulder
Journal:  Gut       Date:  2007-04-30       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.